Incyte Corporation
INCY
Classement en actions
#1001
Incyte Corporation is a biopharmaceutical firm engaged in the research,... Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Prix de l'action
$116.38
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$23.59B
Changement (1 jour)
2.76%
Changement (1 an)
33.31%
Pays
US
Échange Incyte Corporation (INCY)
Catégorie
Healthcare
Ratio P/E pour Incyte Corporation (INCY)
Ratio P/E au October 2026 TTM : 13.72
Selon les derniers rapports financiers et le cours de l'action de Incyte Corporation, le ratio P/E actuel (TTM) est de 13.72. À la fin de l’année 2024, le P/E de l’entreprise était de 438.60.
Historique du ratio P/E pour Incyte Corporation de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 13.72 | -8.39% |
| 2025 | 14.98 | -96.58% |
| 2024 | 438.60 | 1,766.66% |
| 2023 | 23.50 | -55.11% |
| 2022 | 52.34 | 206.89% |
| 2021 | 17.06 | -126.59% |
| 2020 | -64.15 | -252.76% |
| 2019 | 41.99 | -65.96% |
| 2018 | 123.35 | -299.34% |
| 2017 | -61.88 | -134.23% |
| 2016 | 180.75 | -93.94% |
| 2015 | 2.98K | -1,282.99% |
| 2014 | -252.10 | 178.98% |
| 2013 | -90.37 | 85.84% |
| 2012 | -48.63 | 382.05% |
| 2011 | -10.09 | -84.05% |
| 2010 | -63.25 | 1,328.89% |
| 2009 | -4.43 | 132.73% |
| 2008 | -1.90 | -80.47% |
| 2007 | -9.74 | 47.58% |
| 2006 | -6.60 | 52.82% |
| 2005 | -4.32 | -4.45% |
| 2004 | -4.52 | 54.10% |
| 2003 | -2.93 | 30.60% |
| 2002 | -2.25 | -68.03% |
| 2001 | -7.02 | -86.72% |
| 2000 | -52.88 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | 109.73% |
US
|
|
| -28.36 | -306.65% |
US
|
|
| -24.57 | -279.02% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 121.01% |
NL
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.